title: Irinotecan as a second-line chemotherapy for small cell lung cancer: a systemic analysis.
abstract: OBJECTIVE
  This analysis was conducted to evaluate the efficacy and safety of irinotecan based regimens as second-line chemotherapy in treating patients with small cell lung cancer.
  
  
  METHODS
  Clinical studies evaluating the efficacy and safety of irinotecan based regimens as second-line chemotherapy for patients with small cell lung cancer were identified using a predefined search strategy. Pooled response rates (RRs) of treatment were calculated.
  
  
  RESULTS
  In irinotecan based regimens as second-line chemotherapy, 4 clinical studies which including 155 patients with small cell lung cancer were considered eligible for inclusion. In all chemotherapy consisted of irinotecan with or without nedaplatin. Pooled analysis suggested that, in all patients, the pooled RR was 27.1% (42/155) in irinotecan based regimens. Nausea, vomiting, diarrhea and myelosuppression were the main side effects. No grade III or IV renal or liver toxicity was observed. No treatment related death occurred with the irinotecan based treatments.
  
  
  CONCLUSIONS
  This systemic analysis suggests that irinotecan based regimens as second-line chemotherapy are associated with mild response rate and acceptable toxicity for patients with small cell lung cancer.
authors.affiliation: Department of Emergency Medicine, Yan'an Hospital of Kunming Medical University, Kunming, China E-mail : qinfeng6991@sina.com.
authors.forename: Ming-Qian
authors.initials: MQ
authors.lastname: Zhang
authors.forename: Xin
authors.initials: X
authors.lastname: Lin
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Shuang
authors.initials: S
authors.lastname: Lu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*
chemical_list: D009944:Organoplatinum Compounds; D000077146:Irinotecan; C053989:nedaplatin; D002166:Camptothecin